Oxford Bioscience Partners - Boston, MA
|
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences, clean-energy and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)
|
| |
|
|
 |
|
|
 |
|
October 1, 2012
Advisory Board Meetings
@ Oxford Bioscience Partners
October 2, 2012
Annual Limited Partners Meeting
@ Four Seasons Hotel
200 Boylston Street
Boston, MA 02116
February 2, 2009
New England VCs Well Down Midas List—Oxford’s Fambrough Leads Pack
September 19, 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
July 6, 2007
Oxford Bioscience Keeps Successes on the QT
January 24, 2012
Glori Energy Raises $20 Million --
moreJanuary 16, 2012
Astex Announces Early Transfer of Epigenetics Project to GSK --
moreJanuary 6, 2012
Shell Strikes Coalbed Natural Gas Recovery R&D Deal with Luca Tech --
moreJanuary 6, 2012
Xencor Receives U.S. Patent for Monoclonal Antibody Engineering that Extends Duration of Action --
moreJanuary 4, 2012
Glori Energy Signs Contract with Brazil’s Petrobras --
moreJanuary 4, 2012
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer --
moreDecember 21, 2011
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis --
moreDecember 19, 2011
VaxInnate Licenses Recombinant Flu Vaccines To CJ CheilJedang Corporation of South Korea --
more
|
|
|
|